Format

Send to

Choose Destination
Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Author information

1
Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.
2
Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA. Electronic address: cbenes@mgh.harvard.edu.

Abstract

Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient's living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care.

KEYWORDS:

NSCLC; patient-derived cancer cells; personalized medicine

PMID:
29241554
PMCID:
PMC5745232
DOI:
10.1016/j.celrep.2017.11.051
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center